Comparison of intravitreal dexamethasone implant and anti-VEGF drugs in the treatment of retinal vein occlusion-induced oedema: a meta-analysis and systematic review

Shuai Ming,1,2 Kunpeng Xie,2 Mingzhu Yang,3 Huijuan He,2 Ya Li,2 Bo Lei1,2,3

ABSTRACT

Objective To compare the efficacy and safety of intravitreal dexamethasone (DEX) implant and anti-vascularendothelial growth factor (anti-VEGF) agents in the treatment of macular oedema secondary to retinal vein occlusion (RVO).

Design Systematic review and meta-analysis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE).

Data sources PubMed, Cochrane Library and ClinicalTrials.gov registry were searched from inception to 10 December 2019, without language restrictions.

 Eligibility criteria Randomised controlled trials (RCTs) and real-world observation studies comparing the efficacy of DEX implant and anti-VEGF agents for the treatment of patients with RVO, naïve or almost naïve to both arms, were included.

Data extraction and synthesis Two reviewers independently extracted data for mean changes in best-corrected visual acuity (BCVA), central subfield thickness (CST) and product safety. Review Manager V.5.3 and GRADE were used to synthesise the data and validate the evidence, respectively.

Results Four RCTs and 12 real-world studies were included. An average lower letter gain in BCVA was determined for the DEX implant (mean difference (MD) = −6.59; 95% CI −8.87 to −4.22 letters) administered at a retreatment interval of 5–6 months. Results were similar (MD1month = −12.68; 95% CI −21.98 to −3.37 letters; MD3month = −9.69; 95% CI −12.01 to −7.37 letters) at 6 and 12 months. The DEX implant resulted in comparable or marginally less CST reduction at months 6 and 12 but introduced relatively higher risks of elevated intraocular pressure (RR=3.89; 95% CI 2.16 to 7.03) and cataract induction (RR=5.22; 95% CI 1.67 to 16.29). Most real-life studies reported an insignificant numerical gain in letters for anti-VEGF drugs relative to that for DEX implant. However, the latter achieved comparable efficacy with a 4-month dosage interval.

Conclusion Compared with anti-VEGF agents, DEX implant required fewer injections but had inferior functional efficacy and safety. Real-life trials supplemented the efficacy data for DEX implant.

INTRODUCTION

Macular oedema (MO), the abnormal thickening of the macula, is associated with fluid accumulation in the outer layers of the central retina and is often caused by pathological hyperpermeability of the retinal blood vessels.1 It is a leading cause of central vision impairment in diabetes, retinal vein occlusion (RVO) and posterior segment inflammation.2-4 Increases in the levels of inflammatory mediators and upregulation of vascular endothelial growth factor (VEGF) contribute to vascular leakage, breakdown of blood–retinal barrier5-7 and MO. Anti-inflammatory and anti-angiogenic pharmacotherapies have been developed for MO. However, intracocular drug concentrations cannot be sustained for extended periods after a single administration, necessitating multiple intraocular injections in severe cases. This increases the risk of numerous injection-associated side effects.8-9

The dexamethasone intravitreal implant (DEX implant; Ozurdex) is a recently introduced biodegradable device for the sustained
release of DEX in the vitreous humour. It inhibits the expression of inflammatory cytokines and strengthens the blood–retinal barrier. In June 2009, based on the results of a global clinical study, GENEVA, the US Food and Drug Administration (FDA) approved the DEX implant for the treatment of MO secondary to RVO. It was also approved by the European Union (EU) in 2010 and by the CFDA of China in October 2017. Based on a 3-year MEAD study, the DEX implant was approved for administration to diabetic MO patients in the USA. In the EU, the DEX implant was approved for administration to poorly responding diabetic MO patients and for those who are pseudophakic or ineligible for other therapies.

VEGF inhibitors, such as ranibizumab (RNB) and bevacizumab (Bev), are commonly used as anti-angiogenic agents for the treatment of ME. The BRAVO and its extension study demonstrated the short-term and long-term efficacy of RNB in the treatment of branch retinal vein occlusion (BRVO). Ranibizumab was also reported to be effective in the treatment of MO secondary to central retinal vein occlusion (CRVO). Ranibizumab was approved by the US FDA in June 2010 and by the EU in June 2011 for the treatment of MO secondary to BRVO. Bevacizumab could improve vision in BRVO eyes, as effectively as RNB, and was not inferior to aflibercept (Afl) with respect to visual acuity after 6 months of treatment of eyes with CRVO. Bevacizumab has not yet been approved by the FDA for ocular indications but is widely used as an off-label treatment for MO associated with RVOs owing to its cost-effectiveness.

Both the DEX implant and the anti-VEGF agents are effective in the treatment of MO secondary to RVO. They improve vision and decrease central retinal thickness (CRT). However, few systematic reviews or meta-analyses have been performed to compare their clinical effects and safety. Here, we performed a meta-analysis of randomised controlled trials (RCTs) and a systematic review of real-world evidence to compare these two treatments.

METHODS

Search strategy

A literature search was performed using the Medline and the Cochrane Library electronic databases from inception to 10 December 2019, with no language restrictions. The search items are listed in the online supplementary tables S1,S2. The keywords ‘retinal vein occlusion’ and relevant outcomes were not restricted to include more studies. Other searches were conducted using the ClinicalTrials.gov registry. The original studies and review articles identified in the electronic search were manually examined to identify other potentially eligible papers.

Inclusion and exclusion criteria

Eligible studies had to meet the following criteria: (1) the study population had MO secondary to RVO; (2) the treatment arms were DEX implant and anti-VEGF drug monotherapies; (3) the main outcomes were visual acuity and/or central macular thickness; (4) treatment duration was ≥6 months; (5) studies gathered from ClinicalTrials.gov had a ‘completed’ status and their results were posted; (6) for overlapping patients, only studies with updated and complete information were selected. The exclusion criteria were as follows: (1) most patients in the trial were previously treated with several drugs; (2) treatments were switched in the trial during follow-up.

Outcome measurement

The efficacy outcomes included mean average change in best-corrected visual acuity (BCVA) and mean change in CRT at months 6 and 12. The mean average change in BCVA over time (from the baseline until the end of the first month) reflected the area under the curve and was also recorded, if applicable. Visual acuity was measured using a letter or a logMAR chart, according to the Early Treatment Diabetic Retinopathy Study (ETDRS). The CRT indicators included subfield, foveal thickness and central macular thickness, and were evaluated by optical coherence tomography. The safety outcomes were (1) the total number of serious adverse events (SAEs) and other adverse events (AEs) during the RCTs, (2) an elevation of intraocular pressure (IOP), (3) cataract progression and (4) the other top five AEs.

Data extraction

Two investigators (SM and KX) independently screened the titles and abstracts of the searched studies. Full-text articles were evaluated for eligibility according to the inclusion criteria. Disagreements were resolved by discussion and consensus. A standard form was used to compile baseline characteristics, numbers of patients, drug doses, key outcome indicators and any notes that could bias the results. Incomplete and missing values were requested by email from the corresponding authors of the articles or were calculated using the available information. The formula \( SD = SE \times \sqrt{n} \) was used to calculate the SD when only the SE was reported. GetData software was used to estimate the means and SDs when only charts and graphs (figures) were presented in the paper. To ensure the accuracy and completeness of the collected data, the extracted results were posted to the ClinicalTrials.gov registry as supplements to the published data.

Assessment of study evidence and risk of bias

The RoB V.2.0 tool in the Cochrane Collaboration was implemented to assess the risk of bias for the RCTs. The domains ‘randomization process’, ‘deviations from intended interventions’, ‘missing outcome data’, ‘measurement of the outcome’ and ‘selection of the reported result’ were rated as ‘low risk’, ‘some concerns’ or ‘high risk’. Assessment of the risk of bias for real-life studies was performed according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines. Four of the main domains were assessed and graded as 0 (inadequate), 1 (unclear) or 2 (adequate). The global ideal score was eight points.

Ming S, et al. BMJ Open 2020;10:e032128. doi:10.1136/bmjopen-2019-032128
The strength of the RCT evidence was assessed with the GRADEpro V.3.6 tool according to the quality levels ‘high’, ‘moderate’, ‘low’ and ‘very low’.

**Patient and public involvement**
The relevant literature was analysed and the data therein were compiled. No patients were directly involved in the present study.

**Statistical analysis**
Relative therapeutic efficacy was evaluated by identifying differences in the outcomes between the DEX implant and anti-VEGF agent arms. The mean differences (MDs) were calculated by pooling the study-specific estimates in RevMan V.5.2. The interstudy heterogeneity was assessed by estimating the $I^2$ statistic that quantifies the percentage variation across all studies. $I^2>50\%$ and/or $p<0.05$ were considered to indicate statistical heterogeneity. Subgroup analyses were performed to localise heterogeneity only when more than 10 of the included RCTs were available. An a priori random-effects model (DerSimonian-Laird method) was applied even in the absence of statistically significant inter-study heterogeneity because it yielded highly conservative estimates in the presence of residual heterogeneity. This study adheres to PRISMA’s evidence-based minimum set of items for reporting in systematic reviews and meta-analyses (online supplementary table S3).

**RESULTS**

**Study identification**
Figure 1 shows the process employed for the selection of studies. The search strategy returned 244 possibly relevant records (PubMed: 190; Cochrane Library: 95; ClinicalTrials.gov: 22). Thirty-nine duplicate records were eliminated and 258 potentially eligible studies were identified by reading their titles and abstracts. There were 210 exclusions and 24 other studies were ruled out according to the inclusion criteria after evaluating the full-text articles. Of the 12 real-world studies and 8 RCTs included in
the qualitative assessment, 3 clinical trials identified from ClinicalTrials.gov were excluded. One clinical trial (No. NCT01580020) was an extension study of two previously published RCTs; we referred to the information presented in this study in our meta-analysis but did not add it to the list of RCTs. Thus, 16 studies were systematically reviewed and data from four RCTs were used for the meta-analysis.

Characteristics of the included studies

Table 1 lists the characteristics of the four selected RCTs.22–25 The sample sizes ranged from 20 to 307 eyes. The mean ages and proportions of the sexes were statistically similar for all trials. The anti-VEGF agents were injected monthly for the first 3–5 months and pro re nata (PRN) thereafter. The frequency of DEX implant injection varied from 3 to 6 months. The BCVA and CRT baselines were comparable for both arms. Ranibizumab was administered in three studies27–30 and Bev was used in another study.25 The assessment of risk of bias is shown in figure 2. According to the Cochrane criteria, ‘the measurement of outcome’ and ‘randomization process’ domains were low risk. Studies with open label22 and high rates of lost to follow-up24 could increase the risk of bias with respect to ‘missing outcome data’ and ‘deviations from intended interventions’. The overall assessment (online supplementary table S4) revealed concerns about the potential risk of bias.

Table 2 summarises the characteristics of 12 real-world retrospective studies26–38 included in the systematic review. All these studies included naïve or almost naïve participants. Two studies had a three-arm design.27 30 Ranibizumab was used in the anti-VEGF arm in most of the studies, except in two studies in which Afl was used.27 30 and one study in which Bev was used;34 an unspecified anti-VEGF therapy was performed in one study.35 The baseline BCVA and CRT were comparable in both arms except in one study,26 wherein the recruited patients presented with relatively severe BCVA and CRT. After one baseline injection, DEX was administered as PRN every 427–30 or 6 months31 34 or at an unreported interval.

A PRN protocol was applied monthly in the anti-VEGF arms. Four studies27 29 34 35 had a low risk of bias. None of the real-world trials reported adequate control measures for confounding variables. Flawed outcome reporting tended to lower the scores.

Results of the meta-analysis

Average change in BCVA

At month 6, two studies23 24 reported improvements in BCVA in 487 eyes, measured based on letters according to ETDRS. At month 12, three studies22–24 involving 478 eyes reported BCVA data. Data extracted from an extensive study21 (No. NCT01580020) were added to the two aforementioned studies.23 24 The meta-analysis indicated an average reduction in letter gain for BCVA in the DEX implant arm during each study period (MD=−6.59; 95% CI −8.87 to −4.22 letters) when the drug was administered at a retreatment interval of 5–6 months. A single DEX implant injection was less effective in improving BCVA than the anti-VEGF injection administered at the standard frequency (MD month 6=−12.68, 95% CI −21.98 to −3.37 letters) at month 6. With a retreatment interval of 5–6 months, where required, the DEX implant could still achieve a comparatively lower letter gain at month 12 (MD month 12=−9.69; 95% CI −12.01 to −7.37 letters; figure 3).

Average change in CRT

Gado et al25 did not report details of the data for CRT improvement at month 6. However, we estimated these values on the basis of the information reported in a letter37 written by the authors in response to queries posed by a peer reviewer of their study. Thus, three studies23–25 with 547 eyes and three studies22–24 with 457 eyes were analysed at months 6 and 12, respectively. A meta-analysis of reduction in CST at month 6 numerically favoured the anti-VEGF therapy. There was no significant difference between the two arms (MD month 6=0.01µm, 95% CI −25.53 to 225.56µm); however, there was heterogeneity (p<0.001; F=95%). At month 12, the combined MD in CST slightly favoured the anti-VEGF group (MD month 12=41.72µm, 95% CI 5.03 to 78.40µm; figure 3). No heterogeneity was found in the pooled results at month 12 (p=0.59; F=0%).

Safety

Three RCTs22–24 reported detailed safety information for each arm during follow-up. Meta-analysis showed that incidences of total SAEs, eye pain, vitreous floaters and conjunctival haemorrhage occurred at similar risk levels in both arms (p<0.05). The DEX arm was much more likely to present with the other AEs (but not SAEs; RR=1.27, 95% CI 1.16 to 1.39), elevated IOP (RR=3.89, 95% CI 2.16 to 7.03), ocular hypertension (RR=11.03, 95% CI 2.61 to 46.66), and cataract (RR=5.22, 95% CI 1.67 to 16.92; figure 4).

Review of the real-world studies

BRVO-induced me

Nine real-world studies26 28–30 32–34 36 38 reported the efficacy of anti-VEGF and DEX implant in the treatment of BRVO-induced MO. All the nine studies showed significant reduction in CRT after anti-VEGF and DEX treatments. BCVA tended to be associated with a gain in letters and improvement in logMAR following the administration of anti-VEGF and DEX. Two studies revealed no statistically significant change in the DEX arm26 or the worsening of logMAR34 36 with respect to the improvement of BCVA (table 3).

Three studies favoured anti-VEGF therapy because of its relatively superior efficacy in improving BCVA.26 30 34 Kaldirim et al30 used only one DEX implant with a 6-month follow-up, and reported that anti-VEGF therapy was comparatively more efficient in maintaining an increase in visual acuity and in reducing CRT. When the DEX implant was administered PRN at 6-month intervals, the DEX arm presented with 0.19 logMAR visual loss (0.21
Table 1  Characteristics of the randomised controlled trials included in the review

| Study   | Study period (months) | Treatment arms       | Age (years) | Sex (M/F) | MO duration (months) | Drug regimen | Aetiology | Mean dose frequency (months) | No. of injections/implants | Eyes (n) | Baseline BCVA (letters) | Baseline CRT (μm) |
|---------|-----------------------|----------------------|-------------|-----------|----------------------|--------------|-----------|----------------------------|--------------------------|-----------|-------------------------|------------------|
| COMO22  | 12                    | DEX implant 0.7 mg   | 68.4 (10.6) | 92/62     | NA                   | 1 implant at months 0, 5; 1 optional implant at month 10 or 11 | BRVO        | 1 implant at month 0        | 4.8                      | 2.5        | 154                     | 56.6 (10.9)     |
|         |                       | Ranibizumab 0.5 mg   | 65.5 (12.0) | 87/66     | NA                   | 5x monthly doses, then PRN | BRVO        | 1.5                       | 8                        | 153        | 59.2 (10.9)             | 544 (168)       |
| COMRADE-B23 | 6*                  | DEX implant 0.7 mg   | 65.6 (10.0) | 61/57     | ≤6                   | 1 implant at month 0 | BRVO        | 6.0                       | 1.0                      | 118        | 57.2 (11.9)             | NA              |
|         |                       | Ranibizumab 0.5 mg   | 65.7 (10.9) | 50/76     | ≤6                   | 3x monthly doses, then PRN | BRVO        | 1.2                       | 4.9                      | 126        | 58.1 (12.0)             | NA              |
| COMRADE-C24 | 6*                  | DEX implant 0.7 mg   | 66.9 (12.4) | 73/46     | 1.17 (1.87)          | 1 implant at month 0 | CRVO        | 6.0                       | 1.0                      | 119        | 51.5 (15.6)             | 705.2 (231.1)  |
|         |                       | Ranibizumab 0.5 mg   | 65.3 (11.4) | 72/52     | 1.27 (1.20)          | 3x monthly doses, then PRN | CRVO        | 1.3                       | 4.5                      | 124        | 51.7 (16.5)             | 723.8 (245.9)  |
| Gado et al25 | 6                   | DEX implant 0.7 mg   | 68.4 (11.48)| 20/10    | NA                   | 2x per 3 months | CRVO        | 3.0                       | 2.0                      | 30         | 0.6 logMAR              | 548.5 (68.7)   |
|         |                       | Bevacizumab 1.25 mg  | 69.1 (8.56) | 20/10    | NA                   | 3x monthly doses, then PRN | CRVO        | 1.4                       | 4.3                      | 30         | 0.6 logMAR              | 544.1 (48.7)   |

*Extension study with follow-up time prolonged by another 6 months (not shown in the table).

BCVA, best-corrected visual acuity; BRVO, branch retinal vein occlusion; CRT, central retinal thickness; CRVO, central retinal vein occlusion; DR, diabetic retinopathy; F, female; M, male; MO, macular oedema; NA, not available; PRN, pro re nata.
logMAR gain in bevacizumab (p=0.053) and relatively less CRT reduction (48.98 µm vs 157.15 µm; p<0.05) at 6 months. After another injection at 6 months, the DEX implant attained comparable efficacy in terms of the improvement of BCVA (0.19 logMAR vs 0.23 logMAR) and reduction of CRT (~140.7 µm vs ~160.1 µm) by the end of the study. Ozkaya et al.32 validated the therapeutic advantage of anti-VEGF therapy in a follow-up study for a longer duration (24 months). When an average of 2.7, rather than 5.6, injections were administered, the DEX implant did not significantly improve BCVA (0.06 logMAR gain) by the end of month 24. When 5.6 injections were administered, the DEX implant attained comparable efficacy in terms of the reduction of CRT (241.3 µm vs 146.6 µm; not statistically validated) (table 3).

**CRVO-induced MO**

In six studies,27 28 31–33 36 patients with CRVO-induced MO were recruited. Most of the patients demonstrated substantial CRT reduction and visual gain after the anti-VEGF and DEX treatments. Yucel et al.37 performed a Bonferroni correction (p=0.016) but failed to establish that RNB, Afl and DEX were associated with different visual acuities. Winterhalter et al.28 reported that the RNB group presented with only slight visual gain (0.10 logMAR gain, p=0.071) by month 6. There was a slight visual deterioration (0.08 logMAR loss, p=0.305) when only one implant was administered in the DEX arm.

The administration of DEX implant at a 6-month PRN interval did not reduce CRT (~228.0 vs ~303.3, p=0.003) by month 6, as recurrence of MO was observed in the DEX group. However, RNB and DEX were significantly comparable at increasing VA (8.4 letters vs 6.9 letters) and reducing CRT (~260 µm vs ~197 µm)31 by month 12. In three other studies, it was confirmed that anti-VEGF and DEX therapy were equally effective in treating MO secondary to CRVO32 33 36 (table 3).

**RVO-induced MO**

The DEX implant increased BCVA from the baseline by month 6 (0.3 logMAR gain, p=0.001) and month 12 (0.3 logMAR gain, p=0.005). In contrast, the anti-VEGF drugs were only effective at month 6 (0.1 logMAR gain, p=0.02). There were no significant differences in the augmentation of VA or in the reduction of CRT at 6-month and 12-month visits.35 The long-term (12-month) anatomical and visual outcomes were similar for both the DEX and anti-VEGF groups.

**Safety**

No SE data were reported in the real-world studies. We, therefore, only reviewed the progression of cataract and increase in IOP. Only small increases in IOP and low cataract progression rates were observed in the anti-VEGF arm. In contrast, patients receiving the DEX implant were relatively more susceptible to increases in IOP and cataract opacity (table 3).

**DISCUSSION**

The anti-VEGF and DEX therapies for RVO showed similar effectiveness. Because only a few RCTs were included, the results suggested that one DEX injection every 6 months was comparatively less effective in improving the visual acuity. Even when DEX injections at month 5 or PRN at 5–6-month intervals were added, the anti-VEGF drugs resulted in greater letter gains by month 12. The
### Table 2: Characteristics of the real-world studies included in the review

| Study (year, country) | Study design | n (eyes) | Pretreatment | MO aetiology | Duration of follow-up (months) | Duration of MO (months) | Drug regimen | No. of injections | BCVA baseline (logMAR or letter) | CRT (μm) baseline | Risk of bias |
|----------------------|--------------|----------|--------------|--------------|------------------------------|------------------------|--------------|-------------------|-------------------------------|-----------------|-------------|
| Kumar et al (2019, India) | Prospective, open-label study | RNB: 15 Naïve | BRVO | 6 | 3.71±1.72 | 3 | 0.68±0.13 | 487.5±105.9 | 6 |
| | | DEX: 15 Naïve | – | 3.33±1.26 | 0.7 mg, 1 implant | 1 | 0.64±0.15 | 493.7±100.8 | – |
| Ozkaya et al (2018, Turkey) | Retrospective study | RNB: 46 Naïve | BRVO | 24 | <3 | 3× monthly doses, repeated PRN | 5.6±1.8 | 0.64±0.48* | 530±150* | 6 |
| | | DEX: 41 Naïve | – | – | 1 implant, repeated PRN | 2.7±1.1 | 0.98±0.56 | 591±113 | – |
| Yucel et al (2018, Turkey) | Retrospective single-centre study | RNB: 18 Naïve | CRVO | 6 | 3.38±2.8 | 0.5 mg, PRN | 2.56±1.0 | 0.91±0.44 | 587.8±140.9 | 7 |
| | | At: 16 Naïve | – | 5.31±5.1 | 2 mg, PRN | 2.68±0.9 | 1.14±0.50 | 782.8±248.8 | – |
| | | DEX: 24 Naïve | – | – | 0.7 mg, PRN every 4 months | 1.62±0.5 | 1.11±0.46 | 668.7±193.5 | – |
| Winterhalter et al (2018, Germany) | Retrospective observational study | RNB: 59 Naïve | BRVO or CRVO | 6 | BRVO: 2 (1–5) | 0.5 mg, PRN | 1.9 | BRVO:0.5±0.26 | 505.1±189.1 | 7 |
| | | DEX: 48 93.75% naïve | – | CRVO: 6 | BRVO: 1 | 0.7 mg at baseline, then PRN | 3.35±0.5 | 0.57±0.15 | 483.65±61.18 | – |
| Yuksel et al (2018, Turkey) | Retrospective study | RNB: 14 Naïve | BRVO | ≥6 | 4.1 | 0.5 mg, PRN | 1.9 | 0.91±0.64 | 505.1±189.1 | 7 |
| | | DEX: 15 Naïve | – | 2.6 | 0.7 mg, PRN | 1.3 | 0.96±0.41 | 512.8±142.7 | – |
| Kaldirim et al (2017, Turkey) | Retrospective comparative study | RNB: 22 Naïve | BRVO | 6 | 3.41±0.5 | 3× monthly doses of 0.5 mg, then PRN monthly | 3.64±0.49 | 0.59±0.12 | 466.95±90.17 | 5 |
| | | At: 20 Naïve | – | 3.35±0.5 | 3× monthly doses of 2 mg, then PRN monthly | 3.35±0.49 | 0.57±0.15 | 483.65±61.18 | – |
| | | DEX: 20 Naïve | – | 3.5±0.51 | 1 DEX: 0.7 mg | 1 | 0.59±0.15 | 490.75±89.89 | – |
| Chatziralli et al (2017, Greece) | Retrospective observational study | RNB: 25 Naïve | CRVO | ≥12 | 68%<3 | 3× monthly doses of 0.5 mg, then PRN monthly | 5.1±1.1 | 54.8±7.1 | 586.9±141.3 | 6 |
| | | DEX: 17 Naïve | – | 32%<3 | 0.7 mg at baseline, then PRN every 6 months | 2.1±0.6 | 53.7±11.1 | 597.3±148.8 | – |

*Continued on September 17, 2023 by guest. Protected by copyright.http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2019-032128 on 28 June 2020. Downloaded from https://bmjopen.bmj.com on September 17, 2023 by guest. Protected by copyright.*
| Study (year, country) | Study design | n (eyes) | Pretreatment | MO aetiology | Duration of follow-up (months) | Duration of MO (months) | Drug regimen | No. of injections | BCVA baseline (logMAR or letter) | CRT (µm) baseline | Risk of bias |
|-----------------------|-------------|---------|--------------|--------------|----------------|----------------|-------------|----------------|------------------------|-----------------|-------------|
| Gu et al (2017, China) | Retrospective study | RNB: 32 | Naïve | CRVO: 26 | 6 | NA | One at baseline, repeat once recurrence of MO after 1 months | CRVO: 3.4±1.4 | CRVO: 19.5±18.9 | CRVO: 767.5±121.6 | 5 |
|                       |             | DEX: 32 | Naïve | CRVO: 26 | – | NA | One at baseline, repeat once recurrence of MO after 4 months | CRVO: 1.7±0.7 | CRVO: 11.8±16.2 | CRVO: 910.6±346.4 | – |
| Mayer et al (2015, German) | Retrospective case series | RNB: 52 | Naïve | CRVO: 27 | 12 | <3 | 3× monthly doses of 0.5mg, then PRN monthly | CRVO: 5.4 | CRVO: 18.6±11.2 | CRVO: 589.3±199.1 | 5 |
|                       |             | DEX: 60 | Naïve | CRVO: 31 | – | <3 | NR | CRVO: 2.3 | CRVO: 20.8±10.3 | CRVO: 612.4±205.5 | – |
| Kim et al (2015, Korea) | Retrospective, interventional case series | Bev: 44 | Naïve | BRVO | 12 | 5.10±6.78 | 1.25mg, PRN 0.7mg at baseline then, PRN every 6 months | 1.71±0.47* | 0.55±0.45 | 446.61±109.91 | 7 |
|                       |             | DEX: 28 | Naïve | BRVO | – | 7.23±5.99 | 0.7±0.5 | 477.36±118.59 | – |
| Chiquet et al (2015, France) | Retrospective multicentre study | anti-VEGF: 44 | Naïve | RVO | 12 | 6.1±8 | 3× monthly doses | 6±1.5 | 0.7±0.5 | 558±176 | 7 |
|                       |             | DEX: 33 | Naïve | RVO | – | 5.9±10 | PRN every 4 months | 1.6±0.6 | 0.9±0.5 | 527±199 | – |
| Nghiem-Buffet et al (2014, France) | Retrospective study | RNB: 24 | Naïve | CRVO: 7 | 17 | 5.2±4 | 3× monthly doses then, PRN | CRVO: 5.8±2.9 | CRVO: 7.7±5.6 | NR | 5 |
|                       |             | DEX: 19 | Naïve | CRVO: 7 | 12.5 | – | PRN | CRVO: 1.7±0.8 | CRVO: 1.9±1.0 | NR | – |

*Statistical difference between anti-VEGF and DEX.

Afl, aflibercept; Bev, bevacizumab; BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; DEX, dexamethasone implant; DEX, dexamethasone; NR, not reported; RNB, ranibizumab; VEGF, vascular endothelial growth factor.
GRADE assessment indicated that the overall strength was moderate (online supplementary table S5). The reductions in CRT at month 6 were slightly lower for the DEX group than for the others. A network meta-analysis of comparative efficacy revealed that anti-VEGF monotherapy had 84% probability of being the most effective treatment for BRVO-induced MO, whereas the DEX implant had a 0% chance for the same. The combined CRVO and BRVO cases in the present review corroborate this conclusion.

An earlier review evaluated real-world studies on the safety and efficacy profiles of the DEX implant for diabetic MO. Here, we assessed the same profiles in RVO-induced MO. Pielen et al reviewed the general intravitreal therapy for RVO-induced MO. However, the relative efficacies of the DEX implant and anti-VEGF therapies have seldom, if ever, been investigated. One strength of the current study is that in all the trials included, these profiles in both the arms were directly compared. A previous study showed that patients unresponsive to anti-VEGF therapy responded well to the DEX implant. In the long term after the diagnosis of MO, patients might switch from an anti-VEGF to a DEX regimen. By selecting naive or almost naive RVO patients, recently diagnosed with MO (eg, within 3 months), we lowered the risk of bias and provided evidence for first-line RVO treatment.

**Figure 3** A forest plot diagram showing the mean change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT), comparing dexamethasone (DEX) with anti-vascular endothelial growth factor (anti-VEGF) treatment at different times.
### Table

| Study or Subgroup | Experimental Events Total | Control Events Total | Weight | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|-------------------|--------------------------|----------------------|--------|-----------------------------|-----------------------------|
| **3.1.1 Total of SAEs** |
| COMO              | 12                       | 153                  | 16     | 150                         | 4.6%                        | 0.74 [0.36, 1.50]              |
| COMRADE-B         | 9                        | 118                  | 7      | 126                         | 3.2%                        | 1.37 [0.53, 3.57]              |
| COMRADE-C         | 16                       | 110                  | 10     | 124                         | 4.5%                        | 1.67 [0.79, 3.53]              |
| Subtotal (95% CI) | 390                      | 400                  | 69%    | 125                         | 12.5%                       | 1.15 [0.69, 1.94]              |
| Total events      | 37                       | 33                   |        |                             |                             | Test for overall effect: Z = 0.54 (P = 0.59) |
| Heterogeneity: Tau^2 = 0.05, Chi^2 = 2.58, df = 2 (P = 0.27); I^2 = 23% |
| **3.1.2 Total of other AEs** |
| COMO              | 127                      | 153                  | 104    | 150                         | 12.3%                       | 1.20 [1.05, 1.36]              |
| COMRADE-B         | 89                       | 118                  | 71     | 126                         | 11.6%                       | 1.34 [1.11, 1.61]              |
| COMRADE-C         | 99                       | 119                  | 77     | 124                         | 11.9%                       | 1.34 [1.14, 1.57]              |
| Subtotal (95% CI) | 390                      | 400                  | 69%    | 125                         | 12.5%                       | 1.27 [1.16, 1.39]              |
| Total events      | 315                      | 252                  |        |                             |                             | Test for overall effect: Z = 5.34 (P < 0.0001) |
| Heterogeneity: Tau^2 = 0.00, Chi^2 = 1.58, df = 2 (P = 0.45); I^2 = 0% |
| **3.1.3 Elevated IOP** |
| COMO              | 50                       | 153                  | 16     | 150                         | 6.8%                        | 3.06 [1.83, 5.13]              |
| COMRADE-C         | 38                       | 119                  | 7      | 124                         | 4.4%                        | 5.66 [2.63, 12.17]             |
| Subtotal (95% CI) | 272                      | 274                  | 61.1%  | 124                         | 11.2%                       | 3.98 [2.16, 7.03]              |
| Total events      | 88                       | 23                   |        |                             |                             | Test for overall effect: Z = 4.51 (P < 0.0001) |
| Heterogeneity: Tau^2 = 0.00, Chi^2 = 1.72, df = 1 (P = 0.19); I^2 = 42% |
| **3.1.4 Ocular hypertension** |
| COMO              | 9                        | 153                  | 1      | 150                         | 0.5%                        | 0.82 [0.13, 68.79]             |
| COMRADE-B         | 6                        | 118                  | 0      | 126                         | 0.5%                        | 13.07 [0.79, 243.61]           |
| COMRADE-C         | 6                        | 119                  | 0      | 124                         | 0.5%                        | 13.54 [0.77, 237.77]           |
| Subtotal (95% CI) | 390                      | 400                  | 11%    | 124                         | 18%                         | 11.93 [2.61, 46.66]            |
| Total events      | 21                       | 1                    |        |                             |                             | Test for overall effect: Z = 3.26 (P = 0.001) |
| Heterogeneity: Tau^2 = 0.00, Chi^2 = 0.09, df = 2 (P = 0.96); I^2 = 0% |
| **3.1.5 Eye pain** |
| COMO              | 6                        | 153                  | 9      | 150                         | 2.9%                        | 0.65 [0.24, 1.79]              |
| COMRADE-B         | 13                       | 118                  | 9      | 126                         | 4.0%                        | 1.64 [0.68, 3.47]              |
| COMRADE-C         | 15                       | 119                  | 15     | 124                         | 5.2%                        | 1.04 [0.53, 2.04]              |
| Subtotal (95% CI) | 390                      | 400                  | 8%     | 124                         | 12.2%                       | 1.97 [0.58, 7.17]              |
| Total events      | 34                       | 33                   |        |                             |                             | Test for overall effect: Z = 0.30 (P = 0.77) |
| Heterogeneity: Tau^2 = 0.00, Chi^2 = 1.70, df = 2 (P = 0.43); I^2 = 0% |
| **3.1.6 Vitreous floaters** |
| COMO              | 9                        | 153                  | 9      | 150                         | 3.5%                        | 0.98 [0.40, 2.40]              |
| COMRADE-B         | 3                        | 118                  | 3      | 126                         | 1.4%                        | 1.07 [0.22, 5.19]              |
| COMRADE-C         | 11                       | 119                  | 5      | 124                         | 2.9%                        | 2.29 [0.82, 6.40]              |
| Subtotal (95% CI) | 390                      | 400                  | 8%     | 124                         | 7.8%                        | 1.36 [0.73, 2.52]              |
| Total events      | 23                       | 17                   |        |                             |                             | Test for overall effect: Z = 0.06 (P = 0.96) |
| Heterogeneity: Tau^2 = 0.00, Chi^2 = 1.60, df = 2 (P = 0.45); I^2 = 0% |
| **3.1.7 Conjunctival hemorrhage** |
| COMO              | 28                       | 153                  | 17     | 150                         | 6.3%                        | 1.61 [0.92, 2.82]              |
| COMRADE-B         | 14                       | 118                  | 12     | 126                         | 4.7%                        | 1.23 [0.60, 2.56]              |
| COMRADE-C         | 14                       | 119                  | 16     | 124                         | 5.2%                        | 0.91 [0.47, 1.76]              |
| Subtotal (95% CI) | 390                      | 400                  | 6%     | 124                         | 16.1%                       | 1.27 [0.88, 1.84]              |
| Total events      | 56                       | 45                   |        |                             |                             | Test for overall effect: Z = 1.26 (P = 0.21) |
| Heterogeneity: Tau^2 = 0.00, Chi^2 = 1.65, df = 2 (P = 0.44); I^2 = 0% |
| **3.1.8 Cataract** |
| COMO              | 13                       | 153                  | 2      | 150                         | 1.6%                        | 6.37 [1.46, 27.76]             |
| COMRADE-B         | 4                        | 118                  | 1      | 126                         | 0.8%                        | 4.27 [0.48, 37.67]             |
| COMRADE-C         | 1                        | 119                  | 0      | 124                         | 0.4%                        | 3.13 [0.13, 76.96]             |
| Subtotal (95% CI) | 390                      | 400                  | 9%     | 124                         | 2.7%                        | 5.22 [1.67, 16.29]             |
| Total events      | 18                       | 3                    |        |                             |                             | Test for overall effect: Z = 2.64 (P = 0.004) |
| Heterogeneity: Tau^2 = 0.00, Chi^2 = 0.20, df = 2 (P = 0.90); I^2 = 0% |

### Figure 4
A forest plot diagram showing the safety data, including serious adverse events (SAEs), other adverse events (AEs), and the other top five AEs in dexamethasone (DEX) and anti-vascular endothelial growth factor (anti-VEGF) arms.
### Table 3  Summary of the efficacy and safety in real-world studies

| Study (year, country) | Endpoint time (months) | Arms | Change in mean BCVA at month 6 | Change in CRT (μm) at month 6 | Comparison of the changes in BCVA and CRT | Change in BCVA at month 12 or at the end of follow-up | Change in CRT (μm) at month 12 | Safety |
|-----------------------|------------------------|------|--------------------------------|-----------------------------|-----------------------------------------|---------------------------------|-----------------------------|--------|
| Kumar et al (2019, India) | 6, 12, 24 | RNB | +18 letters† | −213.81† | More gain, equal reduction | −0.15 logMAR† (month 24) | −193† (month 24) | Gain, reduction |
|                        |              | DEX | +9.5 letters† | −207.27† | Less gain, equal reduction | −0.06 logMAR (month 24) | −256† (month 24) | No change, reduction |
| Ozkaya et al (2018) | 6, 12, 24 | RNB | −0.11 logMAR† | −133† | Gain, reduction | −0.15 logMAR† (month 24) | −193† (month 24) | Gain, reduction |
|                        |              | DEX | −0.08 logMAR | −171† | No change, reduction | −0.06 logMAR (month 24) | −256† (month 24) | No change, reduction |
| Yucel et al (2018, Turkey) | 6 | RNB | −0.20 logMAR† | −162.7† | Numerical gain, equal reduction | −0.11 logMAR† | −241.3 (47.8%) | More gain, less reduction (numerically) |
|                        |              | Afl | −0.27 logMAR† | −310.1† | Numerical gain, equal reduction | −0.11 logMAR† | −241.3 (47.8%) | More gain, less reduction (numerically) |
|                        |              | DEX | −0.11 logMAR | −193.8† | Numerical gain, equal reduction | −0.11 logMAR† | −241.3 (47.8%) | More gain, less reduction (numerically) |
| Winterhalter et al (2018, Germany) | 6 | RNB | BRVO: +8 letters, −0.16 logMAR† | −194† | BRVO: equal gain, equal reduction | −0.11 logMAR† | −241.3 (47.8%) | More gain, less reduction (numerically) |
|                        |              | BRVO | CRVO: +5 letters, −0.10 logMAR | −204† | CRVO: no change | −0.11 logMAR† | −241.3 (47.8%) | More gain, less reduction (numerically) |
|                        |              | DEX | BRVO: +10 letters, −0.19 logMAR† | −149† | BRVO: equal gain, equal reduction | −0.11 logMAR† | −241.3 (47.8%) | More gain, less reduction (numerically) |
|                        |              | CRVO | CRVO: −4 letters, 0.08 logMAR | −208† | CRVO: slight loss, equal reduction | −0.11 logMAR† | −241.3 (47.8%) | More gain, less reduction (numerically) |
|                        |              |              |              |              | Comparable BCVA gains and CRT reduction in BRVO |              |              | No systemic AE |
|                        |              |              |              |              | Undertreatment in CRVO |              |              | IOP increase >3 mmHg: 6/15 (53.3%) |
| Yuksel et al(2018, Turkey) | 6–11.9 | RNB | +7.1 letters, −0.12 logMAR | −206.5 (40.9%) | Less gain, more reduction (numerically) | −0.11 logMAR† | −241.3 (47.8%) | Less gain, more reduction (numerically) |
|                        |              | DEX | +13.5 letters, −0.27 logMAR | −166.4 (22.5%) | More gain, less reduction (numerically) | +13.5 letters, −0.27 logMAR† | −146.5 (28.6%) | More gain, less reduction (numerically) |
|                        |              |              |              |              |              |              |              | IOP mean increase: 3mmHg* |
| Kaldirim et al (2017, Turkey) | 6 | RNB | −0.35 logMAR† | −195.36† | More gain, more reduction | −0.11 logMAR† | −241.3 (47.8%) | Less gain, more reduction (numerically) |
|                        |              | Afl | −0.38 logMAR† | −241.06† | More gain, more reduction | −0.11 logMAR† | −241.3 (47.8%) | Less gain, more reduction (numerically) |
|                        |              | DEX | −0.26 logMAR† | −163.15† | Less gain*, less reduction* (ANOVA test) | −0.11 logMAR† | −241.3 (47.8%) | Less gain, more reduction (numerically) |

Continued
| Study                          | Endpoint time (months) | Arms | Change in mean BCVA at month 6 | Change in CRT (μm) at month 6 | Comparison of the changes in BCVA and CRT | Change in BCVA at month 12 or at the end of follow-up | Change in CRT (μm) at month 12 | Comparison of the changes in BCVA and CRT | Safety                              |
|-------------------------------|------------------------|------|--------------------------------|-------------------------------|------------------------------------------|------------------------------------------------|-------------------------------|------------------------------------------|--------------------------------------|
| Chatziralli et al (2017, Greece) | 6–12                   | RNB  | +8.9 letters                   | −303.3                        | More gain, more reduction               | +8.4 letters†                                      | −260 μm†                               | Equal gain, equal reduction            | Cataract: 1/25 (4%), IOP increase: none |
|                               | 6–12                   | DEX  | +4.1 letters                   | −228.0                        | Less gain, less reduction               | +6.9 letters†                                      | −197 μm†                               | Equal gain, equal reduction            | Cataract: 3/17 (17.6%), IOP increase: 2/17 (11.8%) |
| Gu et al (2017, China)         | 6                      | RNB  | CRVO: +10.5 letters†           | CRVO---283.2†                  | Equal gain and reduction                | NR                                             | NR                                         | Stable lens opacities and IOP         |
|                               |                        | DEX  | CRVO: +6.9 letters†            | CRVO---139.8†                  | Equal gain and reduction                | NR                                             | NR                                         | Stable lens opacities, IOP elevation but quite stable |
| Mayer et al (2015, German)     | 6, 12                  | RNB  | +8.9 letters, −0.2 logMAR      | −82.9†                        | NR, NR                                   | CRVO: +6.9 letters, CRVO: +12.5 letters           | CRVO: −200.†                              | CRVO: equal gain, NR                   | No systemic AE                        |
|                               |                        | DEX  | +7.6 letters, −0.1 logMAR      | −191.4†                       | NR, NR                                   | CRVO: +8.4 letters, CRVO: +10.7 letters          | CRVO: −303.9†                             | CRVO: equal gain, NR                   | Cataract progression: 50%, IOP increase: >5mmHg: 50% |
| Kim et al (2015, Korea)        | 6–12                   | Bev  | −0.21 logMAR*                  | −157.15*                      | Gain, more reduction                    | Bev: −160.09                                     | Equal gain and reduction                 | No lens opacity increase ≥2 grades, no IOP increase |
|                               |                        | DEX  | +0.19 logMAR                   | −48.98                        | Loss, less reduction                    | DEX: −140.70                                     | Equal gain and reduction                 | one eye lens opacity increase ≥2 grades, no IOP increase |
| Chiquet et al (2015, France)   | 6–12                   | anti-VEGF | −0.1 logMAR†                  | −138 (−20%)†                  | Equal gain, equal reduction             | −210 (−32%)†                                    | Equal gain and reduction                 | Cataract surgery: 10.9%, IOP>21mmHg: 3.1%* |
|                               |                        | DEX  | −0.3 logMAR†                   | −153 (−17%)†                  | Equal gain, equal reduction             | −137 (−20%)†                                    | Equal gain and reduction                 | Cataract surgery: 7.9%, IOP>21mmHg: 21% |
| Nghiem-Buffet et al (2014, France) | BRVO: 15.8             | RNB  | NR                            | NR                            | −                                        | BRVO: +9.2 letters†                             | NR, NR                                   | No cataract progression, no IOP rise >10mmHg |
|                               |                        | CRVO 18.4 | NR                            | −5                            | −                                        | CRVO: +18.2 letters†                            | NR, NR                                   | Cataract progression: 1 (2.4%), IOP rise >10mmHg: 7 (17%) |
|                               |                        | BRVO 13.2 | DEX  | NR                            | −                                      | CRVO: +5.8 letters†                             | NR, NR                                   | Cataract progression: 2 (7.1%), IOP rise >10mmHg: 12 (3.9%) |
|                               |                        | CRVO 11.4 | DEX  | NR                            | −                                      | CRVO: +16.8 letters†                            | NR, NR                                   | Cataract progression: 3 (8.5%), IOP rise >10mmHg: 5 (1.3%) |

*Statistically significant difference between anti-VEGF and DEX.
†Statistically significant difference from baseline.
Alf, aflibercept; ANOVA, analysis of variance; BCVA, best-corrected visual acuity; Bev, bevacizumab; BRVO, branch retinal vein occlusion; CRT, central retinal thickness; CRVO, central retinal vein occlusion; DEX, dexamethasone implant; IOP, intraocular pressure; NR, not reported; RNB, ranibizumab; VEGF, vascular endothelial growth factor.
Heterogeneity and bias

The advantage of the DEX implant is that it releases dexamethasone slowly for ≤6 months. However, it is maximally effective only at ~2 months after administration. Thereafter, its effectiveness declines steadily to a level that is not significantly better than that of a sham treatment. Gado et al added a second DEX implant after the third month. In COMRADE C and COMRADE B, a single implant was used for the comparison of reduction in CRT during 6 months of follow-up. This heterogeneity could undermine the conclusion of our meta-analysis regarding anatomical outcomes. Further, BRVO and CRVO are different disease entities. Eyes with CRVO did not respond as well to anti-VEGF as those with BRVO. Unlike the COMRADE B study (BRVO), the COMRADE C study (CRVO) reported consistent letter gains (16.9 letters vs 17.3 letters) in the anti-VEGF arm but markedly decreased letter gains (−0.7 letters vs 9.2 letters) in the DEX arm. A similar scenario was observed for the anatomic outcomes. These results partially accounted for the substantial heterogeneity that arose when the functional and anatomical outcomes were combined for month 6.

In the COMO study, BRVO patients were administered DEX therapy on day 1, month 5, and month 10 or 11 (optional). In this randomised head-to-head trial, the efficacy of the DEX implant was not non-inferior to that of eight RNB injections at month 12. In an extension of the COMRADE B and COMRADE C studies, German patients who were followed for another 6 months after adding an optional DEX implant under a European label (retreatment interval ≥6 months) were selected. The meta-analysis demonstrated significant functional and slightly better anatomical improvements without heterogeneity in the anti-VEGF group. Nevertheless, caution must be exercised when interpreting the results. The aforementioned study was open-label and phase IV and its core only included certain parts of the population. Selection bias might have also attenuated the evidence and mitigated the reliability of our conclusion. Fortunately, all the patients included in the extension follow-up had comparable baseline characteristics because the core study was effectively controlled. RCTs with multiple DEX injections administered at intervals of <6 months are nonetheless required to draw a robust conclusion.

Safety concerns

Based on the RCTs, no new safety issues were identified for the anti-VEGF or DEX implant treatments. The anti-VEGF treatment proved to be safer than the DEX treatment for ocular AEs, including elevated IOP, ocular hypertension and predictable cataract progression. These differences in safety risks were verified in our review of the real-world studies. RVO patients with relatively higher baseline IOPs or histories of ocular hypertension and/or glaucoma might benefit from the anti-VEGF treatment performed in accordance with the guidelines. Frequent monitoring of IOP and cataract progression can enable DEX to be effective and safe for patients who are reluctant to receive frequent injections. The study showed that visit burdens did not markedly differ between RVO patients receiving ranibizumab injections and those being administered DEX; the mean numbers of ophthalmology visits were 7.2 vs 6.2 for CRVO and 7.1 vs 6.3 for BRVO, respectively.

Physicians must still focus on the clinical benefits of the drugs when they evaluate treatment options for RVO.

Real-world evidence

As there were only a few head-to-head RCTs, real-world comparisons of the DEX implant and anti-VEGF treatments furnish guidance for drug administration. Our systematic review showed that real-world studies reported first-line DEX use and anti-VEGF therapy in naïve patients. The studies reflected the efficacy of medication under practical conditions in the short (6 months) and intermediate (12 months) terms. Similarly, most studies demonstrated the relative superiority of anti-VEGF drugs in terms of letter gains in visual acuity for BRVO and CRVO patients. However, the differences were not usually statistically significant. There are several possible explanations for the discrepancy between the outcomes of the RCTs and real-life studies. First, compared with that in real-world scenarios, the dosages of anti-VEGF agents were effectively controlled in the RCTs. The typical protocol included three to six consecutive monthly injections followed by PRN. In real-world situations, it is difficult to maintain high injection frequencies, and undertreatment has been reported to occur often during a long-term therapy. Second, unlike in the random allocation design of the RCTs, the choice of therapy depended mainly on the ophthalmological and systemic history of the patients in the real-world studies. Third, patients were selected for the clinical trials according to strict and specific criteria, whereas the patients in daily practice did not meet these restrictions.

Retreatment interval

The injection frequency influenced the treatment efficacy in both the groups. Poorer visual outcomes were observed for undertreated patients in the anti-VEGF group. Under the approved dose regimen, protocols administering DEX according to an as-needed retreatment protocol at 6-month intervals showed significantly or numerically lower efficacy than those administering anti-VEGF drugs. The recurrence of MO was also observed by month 5 in the DEX group. In contrast, when DEX was readministered at 6-month intervals, it resulted in comparable or superior visual letter gains and reduction in CRT. However, the differences were not statistically significant. As shorter dosage intervals were suspected to increase the number of complications, the DEX implant must be readministered at ~4–5 month intervals to maintain an efficacy comparable with that of the anti-VEGF drugs. Hence, greater emphasis and attention should be directed toward real-life trials as their treatment intervals generally approach 4 months.
Limitations

All studies included in the present review were head-to-head RCTs or real-world studies directly comparing the administration of anti-VEGF and DEX for the management of RVO. A major limitation was that only four studies were included in this meta-analysis. Thus, we could not analyse the outcomes for the various types of aetiologies (CRVO/BRVO) or for different anti-VEGF agents (RNB or Bev). Therefore, potential heterogeneities associated with these deficiencies were not resolved based on the short-term data. Second, certain studies in which the DEX implant was administered under the European label might have reported underestimates. Third, our review was based on a 6-month or 12-month treatment duration and included no long-term (>2 years) efficacy trials. Real-world reports help to elucidate outcomes but more RCTs are required to validate our meta-analysis.

CONCLUSIONS

The DEX implant demonstrated inferior functional efficacy than the anti-VEGF agents and was not better in terms of short-term and intermediate-term anatomical outcomes. The short-term data might suggest that patients administered a single DEX implant were undertreated. Although it entails relatively fewer injections, the DEX implant must be dialectically administered for the treatment of MO secondary to RVO because it can result in comparatively higher incidences of AEs, such as elevated IOP and cataract in a first-line treatment scenario. The overall advantages of anti-VEGF drugs were verified in the real-world studies and it was confirmed that the DEX implant could achieve efficacy comparable with that of anti-VEGF therapy when it is administered according to the appropriate treatment protocol. Further RCTs are nonetheless required to reinforce our current analysis.

Acknowledgements

The authors alone are responsible for the content and writing of the paper. We wish to thank Dr Nian Xue for providing manuscript language help and proofreading.

Contributors

SM: data collection, analysis, results interpretation and manuscript writing. XX: data collection and results interpretation. MY: paper revision. BL: protocol development and paper revision. HH and YL: data collection. All authors contributed towards the final paper and agree to be accountable for all aspects of the work.

Funding

The study was supported by the National Natural Science Foundation of China grants (Nos. 81470621, 81770949 to BL), National Key Clinical Specialties Construction Programme of China and Henan Key Laboratory of Ophthalmology and Visual Science.

Competing interests

None declared.

Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication

Not required.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information. No additional data available. All data are fully available without restriction.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Shuai Ming http://orcid.org/0000-0002-7685-880X
Bo Lei http://orcid.org/0000-0002-5487-9095

REFERENCES

1. Johnson MW. Etiology and treatment of macular edema. Am J Ophthalmol 2009;147:11-21.
2. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995;102:7-16.
3. Rothova A, Suttorp-van Schulten MS, Frits Trefters W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-6.
4. Tran VT, Pugliese JG, Chang BG, et al. Macular edema. Surv Ophthalmol 2004;49:470-90.
5. Saishin Y, Saishin Y, Takahashi K, et al. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003;185:210-9.
6. Leal EC, Manivannan A, Hosoya K-I, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 2007;48:5257-65.
7. Miyamoto K, Khoosof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adherence molecule-1 inhibition. Proc Natl Acad Sci U S A 1999;96:10836-41.
8. Grover D, Li TJ, Chong CCW. Intravitreal steroids for macular edema due to diabetic macular edema. Cochrane Database Syst Rev 2008;CD005666.
9. Mitry D, Bursel C, Chartier D. Anti-Vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev 2013;CD009510.
10. Chang-Lin J-E, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52:80-6.
11. Li X, Wang N, Liang X, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. Graefes Arch Clin Exp Ophthalmol 2018;256:59-69.
12. Boyer DS, Yoon YH, Belfort R, et al. Three-Year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904-14.
13. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011;118:1594-602.
14. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusion: long-term follow-up in the horizon trial. Ophthalmology 2012;119:802-9.
15. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2011;118:1124-33.
16. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041-9.
17. Narayanan R, Panchal B, Das T, et al. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL report No. 1. Br J Ophthalmol 2015;99:954-9.
18. Scott IU, VanVeldhuisen CP, Ip MS, et al. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA 2017;317:2072-87.
19. Sterne JAC, Savovic J, Page MJ, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:14898.
20. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence–study limitations (risk of bias). J Clin Epidemiol 2011;64:407-15.
21. Feltgen N, Hattenbach L-O, Bertelmann T, et al. Comparison of ranibizumab versus dexamethasone for macular oedema following open access.
retinal vein occlusion: 1-year results of the COMRADE extension study. *Acta Ophthalmol* 2018;96:e933–41.

22 Bandello F, Augustin A, Tufail A, et al. A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. *Eur J Ophthalmol* 2018;28:697–705.

23 Hattenbach LO, Feltgen N, Bertelmann T, et al. Head-To-Head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). *Acta Ophthalmol* 2017.

24 Hoerauf H, Feltgen N, Weiss C, et al. Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): a European label study. *Am J Ophthalmol* 2016;169:258–67.

25 Gado AS, Macky TA. Dexamethasone intravitreal implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. *Clin Exp Optom* 2014;42:650–5.

26 Ozkaya A, Tarakcioglu HN, Tanir I. Ranibizumab versus dexamethasone implant in macular edema secondary to branch retinal vein occlusion: two-year outcomes. *Optom Vis Sci* 2018;95:1149–54.

27 Yuvel OE, Birinci H, Sullu Y. The short-term efficacy of intravitreal ranibizumab, afibbercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion. *Int Ophthalmol* 2019;39:891–901.

28 Winterhalter S, Eckert A, Vom Brocke G-A, et al. Real-Life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months. *Graefes Arch Clin Exp Ophthalmol* 2018;256:267–79.

29 Yuksel B, Kartı O, Celik O, et al. Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion. *Clin Exp Optom* 2018;101:116–22.

30 Kaldırım HE, Yazgan S. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. *Int Ophthalmol* 2018;38:1549–58.

31 Chatziralli I, Theodossiades G, Kabanarou SA, et al. Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study. *Graefes Arch Clin Exp Ophthalmol* 2017.

32 Gu X, Yu X, Song S, et al. Intravitreal dexamethasone implant versus intravitreal ranibizumab for the treatment of macular edema secondary to retinal vein occlusion in a Chinese population. *Ophthalmic Res* 2017;58:8–14.

33 Mayer WJ, Hadjigoli A, Wolf A, et al. [Comparison of Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab as a First-Line Treatment of Macular Oedema due to Retinal Vein Occlusion]. *Klin Monbl Augenheilkd* 2015;232:1289–96.

34 Kim M, Lee DH, Byeon SH, et al. Comparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion. *Br J Ophthalmol* 2015;99:1271–6.

35 Chiquet C, Dupuy C, Bron AM, et al. Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naive patients with retinal vein occlusion and macular edema: a 12-month follow-up study. *Graefes Arch Clin Exp Ophthalmol* 2015;253:2095–102.

36 Ngheim-Buffet S, Fajnkuchen F, Buffet M, et al. Intravitreal ranibizumab and/or dexamethasone implant for macular edema secondary to retinal vein occlusion. *Ophthalmologica* 2014;232:216–22.

37 Gado AS, Macky TA. Dexamethasone intravitreal implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison—response. *Clin Exp Ophthalmol* 2015;43:497–8.

38 Kumar P, Sharma YR, Chandra P, et al. Comparison of the safety and efficacy of intravitreal ranibizumab with or without laser photoacoagulation versus dexamethasone intravitreal implant with or without laser photoacoagulation for macular edema secondary to branch retinal vein occlusion. *Folia Med* 2019;61:240–8.

39 Regnier SA, Larsen M, Beztuky V, et al. Comparative efficacy and safety of Approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. *BMJ Open* 2015;5:e007527.

40 Bucolo C, Gozzo L, Longo L, et al. Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies. *J Pharmocol Sci* 2018;138:219–32.

41 Pielen A, Feltgen N, Isserstedt C, et al. Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. *PLoS One* 2013;8:e78538.

42 Chiquet C, Bron AM, Straub M, et al. Retinal vein occlusions: therapeutic switch in macular oedema treatment with a 12-month follow-up. *Ophthalmic Res* 2016;55:152–9.

43 JA H, BR F, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. *Ophthalmology* 2010.

44 Çilgûlir D, Çilgûlir M. Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA. *Eye* 2017;31:1112–3.

45 Mathew R, Pearce E, Muniraju R, et al. Monthly OCT monitoring of Ozurdex for macular oedema related to retinal vascular diseases: re-treatment strategy (OCTOME report 1). *Eye* 2014;28:318–26.